Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, ...

A language takes work off your hands, gives it to a compiler, runtime, or toolchain, and charges you somewhere else.

A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

Richard Socher's Recursive put about two-thirds of its $650m raise into one multi-year AWS compute deal, and calls it the smallest it will sign.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Jack Clark, Anthropic’s co-founder, left on paternity leave last November. When he returned in February, he was surprised to ...

Recursive, the AI research company led by Richard Socher, has signed a multi-year, $410 million agreement with Amazon Web ...

This article presents a defense-in-depth approach for securing Model Context Protocol (MCP) deployments in production. It outlines four architectural control layers: safe execution, management ...